(secondQuint)Ipilimumab for Head and Neck Cancer Patients.

 This study will test intratumor microdosing of ipilimumab (antagonistic antibody directed to Cytotoxic T-Lmphocyte-Associated Protein 4 [CTLA-4]) 7-10 days prior to planned surgical resection of tumor and involved lymph nodes in patients with SCCHN.

 Tissue, peripheral blood, saliva and stool samples will be obtained for immunologic end points.

 The primary objective is to assess safety, as determined by the number of surgeries that are delayed.

.

 Ipilimumab for Head and Neck Cancer Patients@highlight

This study is for patients with squamous cell carcinoma of the head and neck (SCCHN).

 This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.

